Metastatic Clinical Trials in Guangzhou, Guangdong
82 recruitingGuangzhou, Guangdong, China
Showing 1–20 of 82 trials
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerAdvanced Solid TumorAdvanced Breast Cancer
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 3
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Metastatic Breast CancerLocally Advanced Breast Cancer
Shandong Suncadia Medicine Co., Ltd.240 enrolled2 locationsNCT07024173
Recruiting
Phase 2Phase 3
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd254 enrolled22 locationsNCT05860465
Recruiting
Phase 1Phase 2
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.146 enrolled2 locationsNCT06167694
Recruiting
Phase 3
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.430 enrolled2 locationsNCT07071337
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 1
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.570 enrolled8 locationsNCT05194982
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 2Phase 3
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd374 enrolled9 locationsNCT05744687
Recruiting
Phase 1
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerRecurrent Breast Cancer
Sun Yat-sen University20 enrolled1 locationNCT06900647
Recruiting
Phase 2
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
Metastatic Triple-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University60 enrolled1 locationNCT06851299
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns
Metastatic Breast Cancer
Sun Yat-sen University800 enrolled23 locationsNCT06551220
Recruiting
Phase 1Phase 2
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.354 enrolled1 locationNCT05435248
Recruiting
Phase 2
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University23 enrolled1 locationNCT06517953
Recruiting
Phase 1Phase 2
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Metastatic Breast CancerAdvanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University120 enrolled1 locationNCT06328387
Recruiting
Phase 3
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University312 enrolled1 locationNCT06278870
Recruiting
Phase 3
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University288 enrolled3 locationsNCT05904964
Recruiting
Phase 3
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Metastatic Breast Cancer
Herui Yao210 enrolled13 locationsNCT04263298